Floatz logo

IMMUNOGLOBULIN G4, ANTI-(HUMAN ANTIGEN RECEPTOR KIR (KILLER CELL IMMUNOGLOBULIN-LIKE)) (HUMAN MONOCLONAL ANTI-KIR(1-7F9) HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL ANTI-KIR(1-7F9) LIGHT CHAIN, DIMER

Multiple Myeloma

National Cancer Institute (NCI)monoclonal_antibodyPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
59/ 100

Competitive context

498 Active assets in the Multiple Myeloma cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Jonsson Comprehensive Cancer Center
Phase 4BBB
Inno-206
University of Arkansas
Phase 3BBB
Hyaluronidase fihj
Massachusetts General Hospital
Phase 4BBB
Busulphan
M.D. Anderson Cancer Center
Phase 4BBB
Filanesib
PETHEMA Foundation
Phase 2BBB

View all 50 →

Same molecule, other indications

IMMUNOGLOBULIN G4, ANTI-(HUMAN ANTIGEN RECEPTOR KIR (KILLER CELL IMMUNOGLOBULIN-LIKE)) (HUMAN MONOCLONAL ANTI-KIR(1-7F9) HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL ANTI-KIR(1-7F9) LIGHT CHAIN, DIMER is also rated in:

smoldering plasma cell myelomaDormant
B
Indicative ·
57 / 100
View asset →
First or Second RelapseDormant
CC
Indicative ·
47 / 100
View asset →
acute myeloid leukemiaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →